Skip to main content

Indian Pharma Network

WAINUA (Eplontersen) Injection

  • Medicine Name: WAINUA
  • Active Ingredient (API): Eplontersen
  • Dosage Form & Strength: Injection: 45 mg/0.8 mL prefilled autoinjector
  • Manufactured By: AstraZeneca/Ionis

Medical Uses

WAINUA (eplontersen), from AstraZeneca and Ionis Pharmaceuticals, is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.

Eplontersen is an antisense oligonucleotide that reduces the production of transthyretin (TTR) protein in the liver, decreasing the accumulation of amyloid deposits in nerve tissue that cause the progressive nerve damage of hATTR amyloidosis.

Warnings & Precautions

  • Reduced vitamin A levels — vitamin A supplementation at the recommended daily allowance is advised during treatment; monitor for visual symptoms.
  • Injection-site reactions may occur.
  • Risk of bleeding has been noted with related antisense drugs; monitor platelet counts periodically.
  • Renal function should be monitored during treatment.

Documentation & Availability

What documents are required to import WAINUA to India?

WAINUA may be imported in the patient’s name only, by patients or government hospitals. The following documentation is required:

  • A valid prescription from a registered neurologist
  • Genetic/diagnostic report confirming hereditary transthyretin-mediated amyloidosis
  • Patient ID proof (issued by the Government of India)
How is the order confirmed?

The order is confirmed only after receipt and verification of a valid prescription.

Is WAINUA available in India?

WAINUA is not commercially marketed in India. It can be legally accessed through the Named Patient Program (NPP).

Sourcing & Delivery

Indian Pharma Network (IPN) can source WAINUA from its authorized distribution network and facilitate supply to patients, doctors, and hospitals under applicable legal provisions.

For WAINUA cost in India and availability, contact IPN at Phone: +91-9310090915 or email info@indianpharmanetwork.in.

Global Approval Status:

  • United States: Approved by the FDA — December 2023.

FAQ

What is WAINUA used for?

WAINUA treats the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Who manufactures WAINUA?

WAINUA is jointly developed by AstraZeneca and Ionis Pharmaceuticals.

How is WAINUA administered?

By once-monthly subcutaneous injection using a prefilled autoinjector, which can be self-administered.

How much does WAINUA cost in India?

Cost depends on treatment duration and sourcing logistics — share your prescription with IPN for a quote.

Contact Patient Support

If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.

Disclaimer

All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.

Product Enquiry